Printer Friendly

INCSTAR RECEIVES FDA CLEARANCE TO MARKET NEW TEST FOR INFECTIOUS MONONUCLEOSIS

INCSTAR   RECEIVES   FDA  CLEARANCE  TO  MARKET  NEW  TEST  FOR  INFECTIOUS
    MONONUCLEOSIS
    STILLWATER, Minn., Oct. 1 /PRNewswire/ -- INCSTAR Corporation (AMEX: ISR) today announced that it has been given 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market its new test for the detection of antibodies to Epstein-Barr Virus Early Antigen. Epstein Barr Virus (EBV) is the causative agent of infectious mononucleosis.
    INCSTAR's assay utilizes enzyme-linked immunosorbent assay (ELISA) technology which has advantages over the traditional indirect fluorescent antibody (IFA) technology.  IFA assays are laborious and require the experience and subjective judgment of an expert technician. The company's ELISA test is simple to perform with clear-cut results.
    With the addition of the EBV Early Antigen test kit, INCSTAR now offers a full line of five tests for the detection of related antibodies to EBV.  Tracking the relative levels of the various antibodies to EBV can be utilized in the diagnosis, confirmation and monitoring of infectious mononucleosis.
    INCSTAR is a Minnesota-based manufacturer and distributor of high quality immunodiagnostic products for health care professionals and manufacturers.  The company is an affiliate of the Italian-based Fiat Group (NYSE: FIA).
    -0-             10/01/92
    CONTACT:  Jack Falker of Swenson Falker Eilertsen Inc., 612-371-0000 or John Booth of INCSTAR, 612-779-1700
    (ISR FIA) CO:  INCSTAR CORPORATION IN:  MTC ST:  MN -- MN001 -- X936  10/01/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 1, 1992
Words:222
Previous Article:KOH-I-NOOR INC. ACQUIRES GRUMBACHER FROM BEROL; TONY MURRAY NAMED AS GRUMBACHER PRESIDENT
Next Article:COVER GIRL COSMETICS SIGNS LANA OGILVIE; BLACK MODEL IN EXCLUSIVE CONTRACT WITH MAJOR COSMETICS COMPANY
Topics:


Related Articles
QUIDEL'S NEW ONE-STEP CONCEIVE(TM) OVULATION TEST CLEARS FDA
GULL LABS RECEIVES FDA CLEARANCE FOR RESPIRATORY INFECTION TESTS
GULL LABS' CHAGAS' TEST RECEIVES FDA CLEARANCE
INCSTAR RECEIVES CLEARANCE TO MARKET NEW CMV-VUE ASSAY
MERIDIAN RECEIVES FDA CLEARANCE TO MARKET NEW IMMUNOCARD PRODUCT TO DIAGNOSE INFECTIOUS MONONUCLEOSIS
INCSTAR RECEIVES FDA 510-K CLEARANCE TO MARKET NEW 'ACTH' DIAGNOSTIC KIT
QUIDEL SUBMITS RAPID CHLAMYDIA TEST TO FDA
QUIDEL RECEIVES FDA CLEARANCE TO MARKET THE FIRST ONE-STEP, WHOLE BLOOD, RAPID H. PYLORI TEST
INCSTAR Receives FDA Clearance to Market Test to Determine Levels of Vitamin D in the Bloodstream
INCSTAR Receives Approval to Market its Test for the Detection and Monitoring of Graves' Disease in Japan

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters